COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02178397
Recruitment Status : Terminated (lack of recruitment)
First Posted : June 30, 2014
Last Update Posted : July 17, 2017
Groupe Francais De Pneumo-Cancerologie
Hoffmann-La Roche
Information provided by (Responsible Party):
Centre Francois Baclesse

Brief Summary:

The current first line treatment of patients with EGFR activating mutation lung cancer is EGFR TKI. Compared to platinum-based chemotherapy, EGFR-TKIs are superior in terms of response rate and progression-free survival. However, an acquired resistance occurs almost constantly. The second-line treatment includes platinum-based chemotherapy in the absence of contraindication. This chemotherapy is then administered after discontinuing EGFR TKIs.

However, a rebound phenomenon of the disease was described in patients who discontinued EGFR TKIs. Some clinical teams therefore recommend, as a precaution, in order to avoid any withdrawal phenomenon, to never discontinue EGFR TKIs in patients developing an EGFR TKI acquired resistance.

It seems therefore useful to conduct a study to better define the therapeutic strategy to adopt in patients developing an acquired resistance after having received EGFR TKIs as first line treatment.

Condition or disease Intervention/treatment Phase

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
Study Start Date : June 2014
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment

INDUCTION chemotherapy: 4 cycles of

  • pemetrexed with cisplatin or carboplatin
  • or gemcitabine with cisplatin or carboplatin in combination with erlotinib

THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib

Active Comparator: STANDARD ARM A

INDUCTION chemotherapy: 4 cycles of

  • pemetrexed with cisplatin or carboplatin
  • or gemcitabine with cisplatin or carboplatin

THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed


Primary Outcome Measures :
  1. Efficacy by PFS [ Time Frame: From date of randomization until the date of first documented progression evaluated every 6-9 weeks ]
    Efficacy will be assessed by the PFS, define as time between randomization of the patient in the study and disease progression (local, regional, distant and second cancer) or death (all causes). Alive patients free of progression will be censored at the last follow-up.

Secondary Outcome Measures :
  1. scores of QoL [ Time Frame: at 4 months after inclusion ]
    difference between the scores of QoL at baseline and at 4 months after inclusion for the three targeted dimensions of EORTC QLQ-C30 (global quality of life, fatigue and physical functioning). A difference or 10 points or more at 4 months after inclusion for one score between the 2 arms will be considered as clinically relevant.

  2. Overall survival [ Time Frame: From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months ]
    Overall survival defined as time interval between randomization and death (all causes). Alive patients will be censored at the last date of news or data cut off

  3. Tumoral response [ Time Frame: every 6-9 weeks ]
    Tumoral response (complete response, partial response, stable disease, progression) according to RECIST 1.1

  4. Toxicities [ Time Frame: From date of randomization until study participation, assessed up to 100 months ]
    Toxicities according to NCI-CTC-AE v.4

  5. Rebound phenomenon (flare) [ Time Frame: within 3 weeks after disease progression before inclusion ]
    Rebound phenomenon (flare) defined by a hospitalization or a death within 3 weeks for disease progression after the end of TKI EGFR treatment (in the arm without EGFR TKI) and date of onset

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Man or woman aged 18 years or more
  • Non-small cell lung cancer carcinoma (NSCLC) cytologically or histologically confirmed
  • Measurable disease according to RECIST 1.1 criteria
  • Life expectancy greater than 12 weeks
  • Performance Status (ECOG) ≤ 2
  • Stage IIIB considered ineligible for thoracic radiotherapy at "curative" doses or stage IV
  • Presence of at least one measurable target lesion
  • Documented disease progression (RECIST 1.1) after first line treatment with erlotinib, during at least 4 months in case of partial or complete response according to RECIST criteria, or 6 months in case of stable disease. The treatment with Erlotinib should not be discontinued for more than 8 days between the progression and the inclusion in the study. The daily dose of Erlotinib should be at least 50 mg.
  • Presence of one of the EGFR activating mutations in the tumor (exon 19 deletion or L858R, G719X or L861Q)
  • One additional line of previous chemotherapy is allowed if administered in adjuvant or neoadjuvant setting and received more than six months before.
  • Prior radiotherapy is allowed if the volume of irradiated marrow is <25% of the total bone marrow. The prior radiotherapy must be completed at least two weeks before study entry
  • Brain metastases are allowed if they are controlled without steroids and if their treatment is completed (radiotherapy and/or surgery). Patients with no symptomatic brain metastases may be included; even if brain metastases are progressive and even if they are the only site of progression (since the investigator considers that irradiation is not required). These metastases have not to be life-threatening (are excluded: cerebellar metastasis ≥ 2 cm, brainstem metastasis, brain metastasis > 3 cm and/or near important functional structure).
  • Normal Liver function (bilirubin ≤ULN, AST - ALT ≤2.5 x ULN, alkaline phosphatase ≤3 x ULN), or in case of liver metastases: alkaline phosphatase, AST-ALT ≤ 5 x ULN
  • Normal renal function: blood creatinine ≤ULN and / or creatinine clearance> 60 ml/min calculated with the MDRD formula
  • Normal blood function: absolute neutrophil count ≥ 1.5 x 109/l and / or platelets ≥ 100 x 109 / l, hemoglobin> 9 g/dl
  • Woman and man under efficient contraception during treatment and at least 6 months after the end of treatment by pemetrexed or platinum or gemcitabine
  • Signed written Informed consent

Exclusion Criteria:

  • Bronchoalveolar, mixed, neuroendocrine and small cell lung cancers
  • Patient with only bone metastases are not eligible
  • All progressive metastatic sites treated locally (surgery, radiotherapy)
  • Superior vena cava syndrome
  • Uncontrolled cardiac disease requiring treatment
  • Congestive heart failure, angina pectoris, significant arrhythmias or history of myocardial infarction within the previous 12 months
  • Neurological or psychiatric disorders
  • Uncontrolled infectious disease
  • Peripheral neuropathy grade≥ 2
  • Definitive contraindication for the use of steroids
  • Inductive anti-epileptic treatments (phenobarbital, phenytoïne)• Previous or concomitant other cancer, including skin cancer (except basal cell cancer of the skin), except in situ treated carcinoma of the cervix , except cancer treated with surgery alone without recurrence for 5 years
  • Pregnant or breastfeeding woman
  • Patient follow-up not achievable
  • Participation in a trial within the last 30 days
  • Patient deprived of liberty as a result of a justice or administrative decision

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02178397

Show Show 35 study locations
Sponsors and Collaborators
Centre Francois Baclesse
Groupe Francais De Pneumo-Cancerologie
Hoffmann-La Roche
Layout table for investigator information
Principal Investigator: Radj GERVAIS, MD Centre François Baclesse - CAEN- FRANCE
Layout table for additonal information
Responsible Party: Centre Francois Baclesse Identifier: NCT02178397    
Other Study ID Numbers: FLARE /GFPC 03-2013
First Posted: June 30, 2014    Key Record Dates
Last Update Posted: July 17, 2017
Last Verified: July 2016
Keywords provided by Centre Francois Baclesse:
lung cancer
EGFR mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action